LivingGLP1
Descriptive only

Weight loss of 5 percent or more

Overweight or obesity without diabetes (adults)

weeks 104 to 182 (target week 104)Hypothetical (as if everyone stayed on treatment)Doses of a drug pooledOdds ratio
1
Randomized trials
2
Treatments
241
Participants
148
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
PLACEBOSEMA_SC
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline BMI or body weight (kg/m2)
effect modifier, prognostic factor; 1 of 1
Type 2 diabetes share in weight trials (percent of participants)
effect modifier; 1 of 1
Sex (percent female)
effect modifier, prognostic factor; 1 of 1
Treatment duration (weeks)
effect modifier; 1 of 1
Lifestyle co-intervention intensity (none standard intensive)
effect modifier, prognostic factor; 1 of 1
STEP 5
S000214
38.550
population codes
77.6104standard

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

No comparability concerns were found.

Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
STEP 5104full_analysisnot statednot statednot statednot statedhypotheticalhypotheticaldouble_blindindustry2018age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the odds ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
STEP 5A1SEMA_SC104arm, responders110 / 132R0021896:Results
STEP 5A2PLACEBO104arm, responders38 / 109R0021896:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab